Original paper
B04 Activity of Larotrectinib in Tropomyosin Receptor Kinase Fusion Lung Cancer
Abstract
Tropomyosin receptor kinase (TRK) fusions involving neurotrophic receptor tyrosine kinase (NTRK)1, NTRK2, and NTRK3 genes occur in a range of tumor types. Larotrectinib, the first FDA-approved highly selective TRK inhibitor, has demonstrated an overall response rate (ORR) of 75% by independent central review across a broad spectrum of tumors that harbor NTRK gene fusions (Drilon et al., NEJM 2018;378:731–9). Here we report updated data on the...
Paper Details
Title
B04 Activity of Larotrectinib in Tropomyosin Receptor Kinase Fusion Lung Cancer
Published Date
Feb 1, 2020
Journal
Volume
15
Issue
2
Pages
S28 - S28
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History